

FOI REF: 24/519 Eastbourne District General Hospital

7th August 2024

Kings Drive Eastbourne East Sussex BN21 2UD

Tel: 0300 131 4500 Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment?

Yes.

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

•	Atezolizumab (Tecentriq).	3
•	Avelumab (Bavencio).	2
•	Carboplatin single agent or in any other combination.	0
•	Carboplatin with Gemcitabine.	8
•	Carboplatin with Paclitaxel.	0
•	Cisplatin single agent or in any other combination.	0
•	Cisplatin with Gemcitabine.	4
•	Cisplatin with Gemcitabine + Nivolumab (Opdivo).	0
•	Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda).	0
•	Nivolumab (Opdivo).	0
•	Pembrolizumab (Keytruda).	0
•	Other active systemic anti-cancer therapy.	2
•	Palliative care only.	

Section 17 – Notice of Refusal:

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

East Sussex Healthcare NHS Trust has no clinical trials open to recruitment for urothelial cancer.

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

•	Atezolizumab (Tecentriq).	3
•	Durvalumab (Imfinzi).	4
•	Nivolumab (Opdivo).	2
•	Pembrolizumab (Keytruda).	1
•	Chemotherapy.	13

- Radiotherapy. ESHT does not deliver Radiotherapy. These patients are referred to University Hospitals Sussex NHS Foundation Trust.
- Chemotherapy AND Radiotherapy. Please see above.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (<u>eshtr.foi@nhs.net</u>), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department esh-tr.foi@nhs.net